Vol.
34
No.
6
June 24, 2011Jun 24, 2011
Free

NCI Lung Cancer Mutation Consortium: Screening For Mutations Can Focus Therapy

Two Trials Presented at ASCO Demonstrate Drop in Death Risk, Increased Survival

OCEANS Study: Avastin Shows Tumor Shrinkage in 79 Percent

Cetuximab Plus Chemoradiation Boosts Survival in Phase II Study

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

Telatinib Demonstrates Positive Results in First-Line Treatment

Barret’s Less of a Risk Factor For Cancer of the Esophagus

New Abiraterone Acetate Results Show Greater Benefit Than Before

MGMT Gene Can Determine Disease Aggressiveness

Phase III Study: Lymphoseek Superior to Vital Blue Dye

Intensity Modulated Therapy Safer Than Three-Dimensional Radiation

Smokers Quitlines Found Effective Regardless of Recruitment Method

Study: Vismodegib Effective Where Surgery is Inappropriate

NCI-Approved Clinical Trials For The Month of June

FDA: Silicone Breast Implants Safe, But Not “Lifetime Device”

FDA Updates Safety Labeling Of 5-Alpha Reductase Inhibitors

Login